TNFRSF4 and neoplasm: The second and third generation CAR T cells include the addition of one or two co-stimulatory signalling domains, such as CD28, CD137 (4-1BB), and/or CD134 (OX-40) [70], resulting in improved T cell proliferation, survival and anti-tumour immune functions [71].